MedTrace Logo

Echinacea Angustifolia (AnxioCalm) in Anxiety

NCT03463018 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-03-24

No results posted yet for this study

Summary

This study evaluates whether Echinacea angustifolia (AnxioCalm) is a safe and effective treatment for mild to moderate Generalized Anxiety Disorder (GAD) symptoms. Half the participants will receive Echinacea angustifolia and half will receive placebo.

Conditions

  • Generalized Anxiety Disorder

Interventions

DIETARY_SUPPLEMENT

Echinacea angustifolia

20 mg tablet of Echinacea angustifolia, standardized for echinacoside (not less than 3%) and alkamides (not less than 0.8%)

DIETARY_SUPPLEMENT

Placebo

Placebo tablet containing matching excipients to the active intervention

Sponsors & Collaborators

  • Simon Khechinashvili University

    collaborator UNKNOWN

  • EuroPharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Marina Janelidze, PhD MD · Simon Khechinashvili University Hospital, I.Chavchavadze 33, 0162, Tbilisi, Georgia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-06
Primary Completion
2020-10-03
Completion
2021-12-15

Countries

  • Georgia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03463018 on ClinicalTrials.gov